[Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction].
The serum concentration of thalidomide in multiple myeloma (MM) patients with renal insufficiency has not been investigated in Japan. We examined the serum concentration of thalidomide 12 and 16 hours after administration in 5 patients with MM (one with normal renal function and four with renal insufficiency, including one on hemodialysis (HD)) taking 100-200 mg/day. Concentrations 12 and 16 hours after administration corresponded to those before and after HD, respectively, in the patient on HD. The thalidomide concentration was not significantly increased by renal insufficiency. We could not detect any correlation between the concentration of thalidomide and its clinical effect. Since the elimination of thalidomide during HD seems to be greater than during the same period on a non-HD day, it was suggested that thalidomide could be eliminated by HD. The concentrations 12 hours after administration were similar with or without HD. From these results, even in Japanese patients, the thalidomide dosage need not be modified for renal insufficiency and HD.
Arai
Ayako
A
Department of Hematology, Tokyo Medical and Dental University.
Hirota
Ayako
A
Fukuda
Tetsuya
T
Tohda
Shuji
S
Mori
Yoshihiro
Y
Terada
Yoshio
Y
Sasaki
Sei
S
Miura
Osamu
O
D000368:Aged; D044466:Asian People; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D007668:Kidney / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications* / Q000378:metabolism*; D013792:Thalidomide / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics
D007166:Immunosuppressive Agents; D013792:Thalidomide